Meeder Asset Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-39
| Closed | -$7K | – | 2570 |
|
|
2021
Q3 | $7K | Sell |
39
-1
| -3% | -$131 | ﹤0.01% | 1830 |
|
|
2021
Q2 | $5K | Hold |
40
| – | – | ﹤0.01% | 1979 |
|
|
2021
Q1 | $5K | Sell |
40
-5
| -11% | -$646 | ﹤0.01% | 1882 |
|
|
2020
Q4 | $6K | Sell |
45
-742
| -94% | -$87K | ﹤0.01% | 1185 |
|
|
2020
Q3 | $89K | Sell |
787
-4,743
| -86% | -$472K | 0.01% | 820 |
|
|
2020
Q2 | $528K | Buy |
5,530
+2,568
| +87% | +$248K | 0.03% | 352 |
|
|
2020
Q1 | $266K | Buy |
+2,962
| New | +$230K | 0.02% | 495 |
|
|
2019
Q2 | – | Sell |
-123
| Closed | -$6K | – | 2197 |
|
|
2019
Q1 | $6K | Sell |
123
-229
| -65% | -$10.1K | ﹤0.01% | 1376 |
|
|
2018
Q4 | $15K | Buy |
352
+229
| +186% | +$11.4K | ﹤0.01% | 1149 |
|
|
2018
Q3 | $7K | Sell |
123
-4
| -3% | -$197 | ﹤0.01% | 1264 |
|
|
2018
Q2 | $6.16K | Hold |
127
| – | – | ﹤0.01% | 1223 |
|
|
2018
Q1 | $5K | Sell |
127
-104
| -45% | -$4.42K | ﹤0.01% | 1252 |
|
|
2017
Q4 | $10K | Buy |
231
+62
| +37% | +$2.33K | ﹤0.01% | 1132 |
|
|
2017
Q3 | $6K | Sell |
169
-85
| -33% | -$2.95K | ﹤0.01% | 1232 |
|
|
2017
Q2 | $8K | Hold |
254
| – | – | ﹤0.01% | 1065 |
|
|
2017
Q1 | $7K | Buy |
254
+6
| +2% | +$158 | ﹤0.01% | 975 |
|
|
2016
Q4 | $6K | Buy |
+248
| New | +$7.86K | ﹤0.01% | 842 |
|
Meeder Asset Management's XLRN Position: Q4 2021 in Review
Meeder Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 39 shares — an estimated $7K sold.
Meeder Asset Management first reported a position in XLRN in Q4 2016 and held it in 17 quarters. The position peaked at $528K in Q2 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Meeder Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Meeder Asset Management sold 39 Acceleron Pharma shares in Q4 2021, an estimated $7K.
- Meeder Asset Management first reported a position in Acceleron Pharma in Q4 2016 and held it in 17 quarters.
- Meeder Asset Management's Acceleron Pharma position peaked at $528K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.